Sevoflurane for Acute ischemic stroke

Inclusion criteria

• {"criterion_text":"- Age >18 years\n- Acute ischemic stroke within 24 hours from the last time seen well (LTSW), undergoing emergency endovascular treatment (EVT), with or without prior thrombolysis.\n- Intracranial occlusion in the anterior circulation, including occlusions in segments M1 and M2 of the middle cerebral artery and/or the terminal portion of the internal carotid artery (TICA). Tandem lesions affecting extracranial segments of the internal carotid artery will also be included.\n- Alberta Stroke Program Early CT Score (ASPECTS) ≥6 on baseline computed tomography (CT).\n- Pre-stroke modified Rankin Scale (mRS) score of 0–3.\n- Indication for general anesthesia at the start of the procedure (<30 minutes from femoral puncture) due to one of the following reasons: • Confusion or lack of patient cooperation. • Technical difficulties, such as complex arterial access, vascular tortuosity, need for extra- or intracranial stent placement, distal/medium vessel occlusions, among others. • Treating team's preference.\n- Ability of the patient or the family member/legal representative to provide informed consent."}

Exclusion criteria

• {"criterion_text":"- Presence of hemorrhagic lesions on baseline CT.\n- Occlusions in the anterior cerebral artery (ACA).\n- Occlusions in the posterior circulation, including vertebral, basilar, or posterior cerebral arteries (PCA).\n- Hemodynamic instability.\n- Acute respiratory failure requiring orotracheal intubation\n- Decision to perform general anesthesia due to complications during the endovascular treatment.\n- Known hypersensitivity to propofol, sevoflurane, or any of their excipients.\n- Personal or family history of malignant hyperthermia, or suspected susceptibility to malignant hyperthermia (contraindication to halogenated anesthetics such as sevoflurane).\n- History of a previous severe adverse reaction to halogenated anesthetics, including hepatotoxicity associated with their use."}

Primary endpoints

• {"endpoint_text":"- The primary outcome of the study will be the final infarct volume (FIV), assessed by Fluid-Attenuated Inversion Recovery (FLAIR) sequence on magnetic resonance imaging (MRI) follow-up at 72 hours post-treatment ± 24 hours.","definition_or_measurement_approach":"Final infarct volume (FIV) assessed by FLAIR MRI at 72 hours post-treatment ±24 hours."}

Spain

Earliest CTIS Part Ii Submission Date

30-03-2026

Latest Decision Or Authorization Date

07-04-2026

Processing Time Days

8

Number Of Sites

7

Number Of Participants

330

Primary sponsor

Full Name

Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau

Organisation Type

Hospital/Clinic/Other health care facility

Country Of Registered Address

Spain